Treatment with moderate doses of hydroxyurea in drepanocytosis;Tratamiento con dosis moderada de hidroxiurea en la drepanocitosis

Revista Cubana de Hematologia, Inmunologia y Hemoterapia

Volumn 24, Issue 2, 2008, Pages

  Machín García, Sergio ^a   Svarch, Eva ^a   Agramonte Llanes, Olga ^a   Núñez Quintana, Aramís ^a   Menéndez Veitía, Andrea ^a   Hernández Padrón, Carlos ^a   Mesa Cuervo, José ^a   Nordet Carrera, Ileana ^a   Boch, Lisbet ^a  

^a INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA   (Cuba)

Author keywords

Acute thoracic syndrome; Drepanopcytic anemia; Hydroxyurea; Painful vasoocclusive crisis

Indexed keywords

EID: 56649100624     PISSN: 08640289     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Powars D, Chan LS, Schroeder Wa. The variable expression of sickle cell disease is genetically determined. Semin Hematol 1990;27:360_76.
2. Stuart M, Nagel R. Sickle-cell disease. Lancet 2004;364:1343-59.
3. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-24.
4. Charache S, Terrin ML, Moore RD, Dover GT, Barton FB, Eckert SU, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Eng J Med 1995;332:1317-22.
5. Kinney TR, Helms RN, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS sutdy, a Phase I/II trial. Blood 1999;94:1550-4.
6. Fester A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-32.
7. Zora RR, Buchanan GR. Expanding the role of hydroxyurea in children with sickle cell disease. J Pediatr 2004;145:287-8.
8. Steinberg MH, Lu ZH, Borton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 2001;89:1078-88.
9. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-4.
10. Orringer EP, Blythe DG, Johnson AE, Phillips GJ, Dover GJ, Parker JC. Effects of hydroxyurea on fetal hemoglobin and water content in the red blood cells of dogs and of patients with sickle cell disease. Blood 1991;78:212-6.
11. Ballas SK, Dover GJ, Charache S. Effets of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-11.
12. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Brit J Haematol 2003;120:177-86.
13. Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H2O2 production of polymorphonuclear neutrophil from patients with sickle cell anemia. Blood 2002;99:2297-303.
14. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999;55:1006-10.
15. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea. Hematology 2000;90:3370-7.
16. Davies S, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev 2003;17:99-107.
17. Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994;83:1124-8.
18. O'Braski EE, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell disease receiving hydroxyurea therapy. J Am Dermatol 2001;44:859-61.
19. Moore RD, Charache S, Terrin ML, Barton F, Ballas S. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000;64:26-31.
20. Betke K, Marti HR, Schlit L. Estimation of small percentage of foetal haemoglobin. Nature 1959;184(Suppl 24):1877-8.
21. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risk and benefits up to 9 years of treatment. JAMA 2003;289:26-31.
22. Zimmerman SA, Shultz NH, Davis JS, Pickens CV, Mortier NA, Howard TA. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45.
23. Kutlar A, Woods KF, Clair B. Long term use of hydroxyurea in adults with sickle cell disease: A large single centre experience. Blood 2000;96:10a (abstract).